Moderna, Inc. Files 8-K on Financials
Ticker: MRNA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1682852
| Field | Detail |
|---|---|
| Company | Moderna, Inc. (MRNA) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $3.0, $9.5 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, results-of-operations
Related Tickers: MRNA
TL;DR
Moderna dropped its 8-K on Jan 13, 2025 - check financials!
AI Summary
On January 13, 2025, Moderna, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, providing an update on the company's performance. Moderna, Inc., incorporated in Delaware, is headquartered at 325 Binney Street, Cambridge, MA.
Why It Matters
This 8-K filing provides investors with crucial, up-to-date information on Moderna's financial health and operational results, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Numbers
- 001-38753 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-3467528 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Moderna, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 325 Binney Street, Cambridge, MA 02142 (address) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific financial information is detailed in the 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are within the attached documents.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated January 13, 2025.
What is Moderna, Inc.'s principal executive office address?
Moderna, Inc.'s principal executive offices are located at 325 Binney Street, Cambridge, MA 02142.
In which U.S. state is Moderna, Inc. incorporated?
Moderna, Inc. is incorporated in Delaware.
What is the SEC file number for Moderna, Inc.?
Moderna, Inc.'s SEC file number is 001-38753.
Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-13 07:03:24
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
- $3.0 — e states that (i) the Company generated $3.0-3.1 billion in product sales (unaudited
- $9.5 billion — s of December 31, 2024 is approximately $9.5 billion. The information in this Item 2.02 is
Filing Documents
- mrna-20250113.htm (8-K) — 31KB
- exhibit991-01132025.htm (EX-99.1) — 27KB
- 0001682852-25-000002.txt ( ) — 185KB
- mrna-20250113.xsd (EX-101.SCH) — 2KB
- mrna-20250113_lab.xml (EX-101.LAB) — 21KB
- mrna-20250113_pre.xml (EX-101.PRE) — 12KB
- mrna-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025 , Moderna, Inc. (the "Company") issued a press release (the "Press Release") in connection with the Company's presentation on the same date at the 43rd Annual J.P. Morgan Healthcare Conference. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2024. Specifically, the Press Release states that (i) the Company generated $3.0-3.1 billion in product sales (unaudited) for the fiscal year ended December 31, 2024, and (ii) the Company's current expectation with respect to its cash, cash equivalents and investments in marketable securities (unaudited) as of December 31, 2024 is approximately $9.5 billion. The information in this Item 2.02 is unaudited and preliminary and does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended December 31, 2024, or financial condition as of December 31, 2024. The audit of the Company's financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information in this Item 2.02.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01. The information contained in Items 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 MODERNA, INC. By: /s/ Shannon Thyme Klinger Shannon Thyme Klinger Chief Legal Officer